Page last updated: 2024-08-25

rosiglitazone and Pheochromocytoma

rosiglitazone has been researched along with Pheochromocytoma in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aguilera, MC; Bronfman, FC; Bronfman, M; Contador, D; Fuenzalida, KM; Piderit, DG; QuiƱones, V; Ramos, PC; Rigotti, A1
Chang, MS; Choi, OK; Kim, SW; Kim, SY; Park, KS; Shin, CS1

Other Studies

2 other study(ies) available for rosiglitazone and Pheochromocytoma

ArticleYear
Peroxisome proliferator-activated receptor gamma is a novel target of the nerve growth factor signaling pathway in PC12 cells.
    The Journal of biological chemistry, 2005, Mar-11, Volume: 280, Issue:10

    Topics: Animals; Cell Survival; Gene Deletion; Nerve Growth Factors; PC12 Cells; Pheochromocytoma; PPAR gamma; Rats; Receptor, trkA; Receptors, Nerve Growth Factor; Recombinant Proteins; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transcription, Genetic; Transfection

2005
Thiazolidinediones inhibit the growth of PC12 cells both in vitro and in vivo.
    Biochemical and biophysical research communications, 2008, Jun-27, Volume: 371, Issue:2

    Topics: Adrenal Gland Neoplasms; Animals; Antineoplastic Agents; Caspase 3; Cell Proliferation; Cyclin E; Cyclin-Dependent Kinase 2; Humans; Ki-67 Antigen; Mice; Nerve Growth Factor; Neurons; PC12 Cells; Pheochromocytoma; Pioglitazone; PPAR gamma; Rats; Rosiglitazone; Thiazolidinediones

2008